Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders

A Los Angeles jury awarded $40 million—$18 million to Monica Kent and $22 million to Deborah Schultz and her husband—to two women who say Johnson & Johnson’s talcum powders caused their ovarian cancer; J&J said it will appeal and noted it has won 16 of 17 ovarian-cancer trials it previously tried. The verdict is the latest in a high-profile, costly legal campaign over talc, coming after an October $966 million mesothelioma award and amid J&J’s 2020 switch to cornstarch in North America and the company’s 2023 halt to worldwide talc sales; a U.S. bankruptcy judge also rejected J&J’s proposed $9 billion settlement for talc-related claims in April. The decision underscores ongoing litigation and reputational risk for J&J despite the company’s insistence, backed by some scientific reviews, that talc is safe, and could have continued financial implications depending on appeals and future verdicts.

Analysis

A Los Angeles jury awarded $40 million on Friday to two women who alleged Johnson & Johnson's talcum powders caused their ovarian cancer, allocating $18 million to Monica Kent and $22 million to Deborah Schultz and her husband, and the company said it will appeal the liability verdict. This verdict follows a broader litigation backdrop that includes an October $966 million mesothelioma award, J&J's 2023 halt to worldwide talc sales, its 2020 switch to cornstarch in North America, and a U.S. bankruptcy judge's April denial of a proposed $9 billion talc settlement.

J&J asserts it has prevailed in 16 of 17 ovarian-cancer trials previously tried and cites independent scientific evaluations that find talc safe, creating a mixed legal record that increases outcome uncertainty. The combination of successful defenses and large plaintiff awards to date suggests case-by-case volatility in verdict sizes and uncertain aggregate liability despite product changes and corporate defenses.

Market signals show moderately negative sentiment (sentiment_score -0.5) with a modest market-impact score (0.35), indicating reputational and litigation risk that could produce episodic stock volatility rather than immediate systemic disruption. Investors should track appellate outcomes, company disclosures on reserves and insurance recoveries, and any regulatory or scientific developments that could change expected cash flows or capital allocation decisions.

Key Decisions for Investors

• Monitor the appellate process and calendar closely and treat near-term holdings as event-driven until appellate rulings clarify liability exposure
• Scrutinize upcoming J&J filings for reserve increases, cash impact and insurance recoveries and adjust position sizing or add hedges if material reserves are recorded
• Consider underweighting or hedging J&J exposure relative to benchmark until there is clarity on aggregate talc liabilities or a negotiated settlement, given the potential for episodic multi-hundred-million dollar verdicts
• Watch for further large plaintiff verdicts or adverse judicial rulings and reassess sector/holding allocations if litigation momentum shifts materially in plaintiffs' favor